Target Information

Target General Infomation
Target ID
T13251
Former ID
TTDC00033
Target Name
Interleukin-12
Gene Name
IL12A
Synonyms
CLMF p35; Cytotoxic lymphocyte maturation factor 35 kDa subunit; IL-12; NK cell stimulatory factor; NKSF; IL12A
Target Type
Successful
Disease Crohn's disease; Moderate-to-severe rheumatoid arthritis [ICD9:555, 714; ICD10: K50, M05-M06]
Crohn's disease; Inflammatory bowel disease [ICD9: 555, 556; ICD10: K50, K51]
Moderate-to-severe plaque psoriasis [ICD9: 696; ICD10: L40]
Psoriasis [ICD9: 696; ICD10: L40]
Function
Cytokine that can act as a growth factor for activated T and NK cells, enhance the lytic activity of NK/lymphokine- activated Killer cells, and stimulate the production of IFN-gamma by resting PBMC.
BioChemical Class
Cytokine: interleukin
Target Validation
T13251
UniProt ID
P29459
Sequence
MCPARSLLLVATLVLLDHLSLARNLPVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLE
FYPCTSEEIDHEDITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMM
ALCLSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQK
SSLEEPDFYKTKIKLCILLHAFRIRAVTIDRVMSYLNAS
Drugs and Mode of Action
Drug(s) Ustekinumab Drug Info Approved Moderate-to-severe plaque psoriasis [530677], [541942]
Ustekinumab Drug Info Phase 3 Psoriasis [530677], [541942]
Ustekinumab Drug Info Phase 2/3 Crohn's disease; Inflammatory bowel disease [530677], [541942]
STA-5326 Drug Info Phase 2 Crohn's disease; Moderate-to-severe rheumatoid arthritis [528277], [536054]
Inhibitor STA-5326 Drug Info [536292], [536876]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Cytokine-cytokine receptor interaction
Toll-like receptor signaling pathway
RIG-I-like receptor signaling pathway
Jak-STAT signaling pathway
Type I diabetes mellitus
Pertussis
Legionellosis
Leishmaniasis
Chagas disease (American trypanosomiasis)
African trypanosomiasis
Malaria
Toxoplasmosis
Amoebiasis
Tuberculosis
Measles
Influenza A
Herpes simplex infection
Inflammatory bowel disease (IBD)
Allograft rejection
Pathway Interaction Database IL27-mediated signaling events
IL12-mediated signaling events
WikiPathways Toll-like receptor signaling pathway
Aryl Hydrocarbon Receptor Pathway
Allograft Rejection
Regulation of toll-like receptor signaling pathway
References
Ref 528277A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm Bowel Dis. 2006 Jul;12(7):558-65.
Ref 530677Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
Ref 536054Emerging drugs for moderate-to-severe psoriasis. Expert Opin Emerg Drugs. 2005 Feb;10(1):35-52.
Ref 541942(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6885).
Ref 530677Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
Ref 536292Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor. Blood. 2007 Feb 1;109(3):1156-64. Epub 2006 Oct 19.
Ref 536371Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59.
Ref 536876Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis. Arthritis Res Ther. 2008;10(5):R122. Epub 2008 Oct 13.
Ref 537117Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.